---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-003940"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:59:21.339748+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics reports FY2023 net loss of $22.3M; cash runway into Q1 2025

## Summary
- Net loss for FY2023 was $22.3M ($1.71 per share), vs $17.6M ($1.48) in FY2022.
- R&D expenses rose to $11.5M from $8.4M due to Phase 1 trial of GT-02287 for GBA1 Parkinson's disease.
- Cash and marketable securities $16.8M as of Dec 31, 2023; expected to fund operations into Q1 2025.
- Initiated MAD part of Phase 1 trial of GT-02287; data presented at AD/PD 2024 and WORLD Symposium.
- Raised $10.1M gross proceeds from public offering and private placement in 2023.

## SEC filing metadata
- accession: 0001558370-24-003940
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000155837024003940/0001558370-24-003940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000155837024003940/ganx-20240326x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-003940
- JSON: https://secwatch.observer/filing/0001558370-24-003940.json
- Plain text: https://secwatch.observer/filing/0001558370-24-003940.txt

## Key facts
- Earnings Releases
  Gain Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $22.3 million, EPS $1.71.
  - Period: the year ended December 31, 2023
  - Net income: $22.3 million
  - EPS: $1.71
  - Result: reported results
  source text: Net loss for the year ended December 31, 2023 was $22.3 million, compared to a net loss of $17.6 million for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000155837024003940/0001558370-24-003940-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.